Lycia Therapeutics to Present at 2026 Jefferies Global Healthcare Conference
News related to:Lycia Therapeutics · 2 min read
SOUTH SAN FRANCISCO, Calif., Nov. 11, 2026 /CourierPR/ -- Lycia Therapeutics, a clinical-stage biotechnology company focused on developing novel therapeutics to degrade disease-causing extracellular proteins, will present at the 2026 Jefferies Global Healthcare Conference in London. President and CEO Aetna Wun Trombley will deliver the presentation on Wednesday, November 18, 2026, at 3:00 p.m. GMT.
The company’s lead candidates include LCA-0061, a cataLYTACTM degrader of IgE for food allergy and other allergic diseases, and LCA-0321, a LYTAC degrader designed to selectively deplete the autoantibodies that cause Graves’ disease. Lycia Therapeutics, headquartered in South San Francisco, was founded on the groundbreaking work of Nobel laureate Carolyn Bertozzi, Ph.D., a professor of chemistry and HHMI investigator at Stanford University.
The presentation will be accessible via a live webcast in the Investors section of the Lycia Therapeutics website at ir.lyciatx.com. A replay of the webcast will be available for approximately 60 days following the presentation.
Lycia Therapeutics is advancing its proprietary LYTAC (Lysosomal Targeting Chimera) platform to generate cataLYTACTM degraders, which are designed for repeated catalytic elimination of disease-causing proteins. This approach aims to address a range of autoimmune, inflammatory, and allergic diseases, with a particular focus on food allergies and Graves’ disease.
The company’s lead candidate, LCA-0061, is a cataLYTACTM degrader of IgE, targeting food allergies and other allergic conditions. By degrading IgE, LCA-0061 seeks to provide a novel therapeutic approach to manage these allergic reactions. Similarly, LCA-0321, a LYTAC degrader, is designed to selectively deplete the autoantibodies that cause Graves’ disease, a condition characterized by an overactive thyroid gland.
Lycia Therapeutics continues to leverage its innovative platform to develop transformative therapies for patients suffering from a range of debilitating diseases. The company’s commitment to advancing the field of biotechnology through the use of degraders is evident in its ongoing research and development efforts.
The presentation at the 2026 Jefferies Global Healthcare Conference will provide an opportunity for stakeholders and healthcare professionals to learn more about Lycia Therapeutics’ cutting-edge research and its potential impact on the treatment of autoimmune, inflammatory, and allergic diseases.